Exploration of New Treatment in Advanced Pancreatic Cancer
博士 === 國立臺灣大學 === 臨床醫學研究所 === 107 === Pancreatic cancer is highly lethal with great medical unmet needs. The majority of patients have adenocarcinoma. The 5-year overall survival (OS) rate is 5%. At initial diagnosis, only 20% of patients have resectable diseases. Gemcitabine and 5-FU/5-FU analogs a...
Main Authors: | Shih-Hung Yang, 楊士弘 |
---|---|
Other Authors: | Kun-Huei Yeh |
Format: | Others |
Language: | zh-TW |
Published: |
2019
|
Online Access: | http://ndltd.ncl.edu.tw/handle/3tf46y |
Similar Items
-
Erlotinib in the treatment of advanced pancreatic cancer
by: Robin K Kelley, et al.
Published: (2008-03-01) -
Advances of Exosomes in Diagnosis and Treatment of Pancreatic Cancer
by: ZHANG Chi, et al.
Published: (2019-08-01) -
Investigation of treatment strategy for advanced cancer according to treatment of pancreatic cancer
by: XU Kecheng
Published: (2013-10-01) -
Nab-paclitaxel: potential for the treatment of advanced pancreatic cancer
by: Al-Hajeili M, et al.
Published: (2014-02-01) -
Pancreatic Cancer Associated Fibroblasts (CAF): Under-Explored Target for Pancreatic Cancer Treatment
by: Jeffrey Norton, et al.
Published: (2020-05-01)